Advertisement

In Vivo Targeting of Dendritic Cells with Artificial Adjuvant Vector Cells (aAVC) as a Novel Cancer Immunotherapy

  • Shin-ichiro Fujii
  • Jun Shinga
  • Satoru Yamasaki
  • Yusuke Sato
  • Miki Asakura
  • Kanako Shimizu

Abstract

An ideal cancer vaccine would inhibit tumor cells by inducing both innate and adaptive immunity, allowing for specific and long-term cancer immunosurveillance.

Dendritic cells (DCs) and invariant natural killer T (iNKT) cells are excellent targets for this type of tumor immunotherapy development. DCs are innate immune cells that initiate and shape adaptive immunity through naïve T cell priming and chemokine/cytokine secretion, while iNKT cells induce the maturation of endogenous DCs in situ, thereby linking innate and adaptive immunity.

Our laboratory has established a unique method of targeting in vivo DCs using a cell vector system comprised of glycolipid-loaded, mRNA-transfected allogeneic cells. These cells provide iNKT cell activation, DC maturation, and tumor-specific T cell immunity. This unique tool could prove clinically beneficial in the development of immunotherapies against malignant and infectious diseases.

Keywords

iNKT cells Adjuvant effects Dendritic cells α-Galactosylceramide Cross-presentation 

References

  1. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar MV (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201(9):1503–1517CrossRefPubMedCentralPubMedGoogle Scholar
  2. Dondji B, Deak E, Goldsmith-Pestana K, Perez-Jimenez E, Esteban M, Miyake S, Yamamura T, McMahon-Pratt D (2008) Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 38(3):706–719CrossRefPubMedCentralPubMedGoogle Scholar
  3. Fujii S (2008) Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol 29(5):242–249CrossRefPubMedGoogle Scholar
  4. Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged interferon-γ producing NKT response induced with α-galactosylceramide-loaded dendritic cells. Nat Immunol 3:867–874CrossRefPubMedGoogle Scholar
  5. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM (2003) Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. J Exp Med 198(2):267–279CrossRefPubMedCentralPubMedGoogle Scholar
  6. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199(12):1607–1618CrossRefPubMedCentralPubMedGoogle Scholar
  7. Fujii S, Shimizu K, Hemmi H, Steinman RM (2007) Innate Vα14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 220(1):183–198CrossRefPubMedGoogle Scholar
  8. Fujii S, Goto A, Shimizu K (2009) Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. Blood 113(18):4262–4272CrossRefPubMedGoogle Scholar
  9. Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, Barr IG, Doherty PC, Godfrey DI, Turner SJ (2009) Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci U S A 106(9):3330–3335CrossRefPubMedCentralPubMedGoogle Scholar
  10. Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M (2008) Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide. Vaccine 26(15):1807–1816CrossRefPubMedGoogle Scholar
  11. Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI (2008) Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 1(3):208–218CrossRefPubMedGoogle Scholar
  12. Lindqvist M, Persson J, Thorn K, Harandi AM (2009) The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 182(10):6435–6443CrossRefPubMedGoogle Scholar
  13. Liu K, Iyoda T, Saternus M, Kimura K, Inaba K, Steinman RM (2002) Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196(8):1091–1097CrossRefPubMedCentralPubMedGoogle Scholar
  14. Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, Mordoh J, Wainstok R, Bai XF, Liu Y, Steinman RM (2005) Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202(11):1507–1516CrossRefPubMedCentralPubMedGoogle Scholar
  15. Motohashi S, Nakayama T (2009) Natural killer T cell-mediated immunotherapy for malignant diseases. Front Biosci (Schol Ed) 1:108–116CrossRefGoogle Scholar
  16. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ (2004) Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103(2):383–389CrossRefPubMedGoogle Scholar
  17. Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Saint Basile G, Latour S (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444(7115):110–114. doi: 10.1038/nature05257
  18. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, Rossjohn J, Perlmutter P, Cao J, Godfrey DI, Savage PB, Knolle PA, Kolanus W, Forster I, Kurts C (2010) Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 11(4):313–320CrossRefPubMedGoogle Scholar
  19. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S (2007a) Tumor cells loaded with α-galactosylceramide Induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 178(5):2853–2861CrossRefPubMedGoogle Scholar
  20. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S (2007b) Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 204(11):2641–2653CrossRefPubMedCentralPubMedGoogle Scholar
  21. Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, Masuda K, Maeda T, Sugahara H, Sato Y, Matsushita H, Nishida K, Hanada K, Dorrie J, Schaft N, Bickham K, Koike H, Ando T, Nagai R, Fujii SI (2013) Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells. Cancer Res 73(1):62–73. doi: 10.1158/0008-5472.CAN-12-0759
  22. Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101:277–348CrossRefPubMedCentralPubMedGoogle Scholar
  23. Tupin E, Kinjo Y, Kronenberg M (2007) The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 5(6):405–417CrossRefPubMedGoogle Scholar
  24. Van Kaer L (2007) NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 19(3):354–364. doi: 10.1016/j.coi.2007.03.001
  25. Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, Boyaka PN, Kim SH, Horimoto T, Kweon MN, Kang CY (2007) A single intranasal immunization with inactivated influenza virus and α-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25(28):5189–5198CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2015

Authors and Affiliations

  • Shin-ichiro Fujii
    • 1
  • Jun Shinga
    • 1
  • Satoru Yamasaki
    • 1
  • Yusuke Sato
    • 1
  • Miki Asakura
    • 1
  • Kanako Shimizu
    • 1
  1. 1.Laboratory for ImmunotherapyRIKEN Center for Integrative Medical SciencesYokohamaJapan

Personalised recommendations